Skip to main content

Table 1 Demographic, metabolic and HIV characteristics of the patients

From: Soluble CD163 does not predict first-time myocardial infarction in patients infected with human immunodeficiency virus: a nested case–control study

Variable Cases Controls p-valuea
Number of patients 55 182  
Gender (male/female) (%) 50/5 (91/9) 167/15 (92/8)  
Age at time of MI/index date median (IQR), years 49 (42 – 57) 50 (43 – 57)  
Duration of HIV before MI/index date median (IQR), years 10 (6 – 17) 10 (7 – 16) 0.71
Mean duration of therapy before MI/index date median (IQR), years 6 (3 – 8) 6 (3 – 9)  
Intervals between plasma samples    
From sample 1 to initiation ART, median (IQR), days 42 (24 – 76) 49 (32 – 81)  
From initiation of ART to sample 2 median (IQR), days 99 (88 – 123) 109 (87 – 142)  
From sample 3 to MI/index date median (IQR), days 334 (292 – 367) 368 (334 – 408)  
From sample 4 to MI/index date median (IQR), days 52 (27 – 82) 0 (0 – 0)  
Smoking (never/ever) (%) 2/53 (4/96) 6/176 (3/97)  
Blood pressure, systolic median (IQR) 135 (120 – 149) n = 36 125 (115 – 140) n = 87 0.09
CD4 cell count/mm3, median (IQR)¤ 496 (290–688) n = 52 547 (307–800) n = 161 0.78
HIV-RNA copies/mL, median (range)¤ 39 (19–217200) 39 (19–93900) 0.08
Number of patients with HIV-RNA < 400 copies/mL¤ 44 (80%) 146 (89%) 0.12
Creatinine μM, median (IQR)¤ 81 (70–89) 78 (70–88) 0.38
mg/dL, median (IQR) 1.1 (0.9–1.2) n = 48 1.0 (0.9–1.2) n = 148  
Cholesterol mM, median (IQR)¤ 6.3 (5.5–8.0) 5.7 (5.0–6.7) 0.38
mg/dL, median (IQR) 241 (214–309) n = 32 220 (193–255) n = 96
Lipid-lowering treatment (%)# 6 4 0.6
Starting antihypertensive treatment (%)# 13 4 0.07
Starting anti-coagulative treatment (%)# 4 3 0.67
Co-infected with hepatitis B (%) (HbsAg positive) 6 7 0.6
Co-infected with hepatitis C (%) (HCV-Ab-positive) 6 14 0.07
Exposed to ART (%)# 100 100 -
Exposed to NRTI (%)# 100 99.5 0.76
Exposed to abacavir (%)# 56 39 0.007
Exposed to NNRTI (%)# 73 58 0.006
Exposed to PI (%)# 87 84 0.24
  1. a univariate conditional logistic regression.
  2. ¤ plasma sample 4 (at time of MI/index date).
  3. # within the study period.
  4. Abbreviations: ART, Antiretroviral therapy; B-glucose, blood-glucose; HIV, Human immunodeficiency virus; MI, Myocardial infarction; NNRTI, Nonnucleoside reverse-transcriptase inhibitors; NRTI, Nucleoside reverse-transcriptase inhibitors; PI, Protease inhibitors.